Fig. 1

A Schematic view of high-throughput screening (HTS) platform using patient-derived lung cancer organoids (PDOs). (A) Photographs of the proposed cell spotter (ASFA™ Spotter DN) with disposable nozzle and sample dispensing unit. (B) Schematic diagram of module parts for dispensing of ASFA™ Spotter DN. (C) 384-pillar/well plate photograph and 3D cell culture illustration. The lung cancer PDO is mixed with an ECM and is 3D cultured and drug screen on the surface of a 384-pillar plate. (D) Representative bright field (BF) and confocal images of PDOs from day 1 to 6. The lung cancer PDO grows by forming colonies